Skip to main content

New Business Development

New Business Development

At Janssen we take pride in our track record of delivering new products to market including those that originated outside our organization. In addition to our own Research and Development (R&D), we have a history of successfully integrating licensed and partnered products, to create an innovative portfolio focused on delivering meaningful healthcare outcomes for patients. In our five focus therapeutic areas (below), we have established a leadership position through our product portfolio, deep market insights and best in class commercial capabilities.

Building Strong, Long-Term Partnerships

“Collaborations have formed an essential part of our heritage and we are committed to working with our partners to achieve this goal,”
Jane Griffiths, Company Group Chairman, Janssen Europe, Middle East & Africa (EMEA).

The New Business Development team builds strong, long-term collaborations that deliver added value to our partnered programs. Our ambition is to be considered the partner of choice. We already have more than 150 collaborations, across all aspects of the healthcare spectrum, including those with large pharmaceutical companies, biotech companies, academic institutions, public-private partnerships and open campus initiatives.

Our Areas of Interest

Our efforts are focused on five key therapeutic areas:

  • Cardiovascular & Metabolism
  • Immunology
  • Infectious Diseases & Vaccines
  • Neuroscience
  • Oncology

Within these areas the EMEA New Business Development team is interested in partnerships around late stage development, registration or already marketed products. We are keen to discuss well-differentiated opportunities that will deliver value to our patients and will fit with our aspiration of being a transformational medical innovator.

Extend Your Reach

Our operational strength across the entire EMEA region – including Russia, Turkey and other Emerging Markets – will help you extend your reach to many more patients across the globe.

Our team is distributed throughout the EMEA region and this in-depth knowledge of the markets enables us to accurately assess the value of an opportunity in rapidly evolving local market conditions.

Contact Our Team

If you would like to talk to us about your product or a partnership idea, please contact us today. We’ll ensure that you are connected with the appropriate person and that you receive a prompt reply: [email protected].

Visit our global Janssen Business Development Home Page to find information about our global organization for mid- to late-stage development:

Visit our Johnson & Johnson Innovation Center website for information on early-stage development: 


Download information on our regional EMEA NBD team here.

VP New Business
Development EMEA

Patrick Schuler
E: [email protected]

Metabolics and France

Pierre Quelet
E: [email protected]

EMEA Emerging Markets and UK

Ahmed Mohamed
E: [email protected]

Oncology/Hematology and Italy


Neuroscience & Pain and Spain

Leonor Rombert Sousa
E: [email protected]

Infectious Diseases
and Mid-sized-Markets

Ingeborg Vandenbroucke
E:[email protected]

Immunology and Partnership Development


Cardiovascular and Germany

Renier van Dinter
E: [email protected]

HIV, Respiratory Infections and Russia

Dmitri Pakhomov
E: [email protected]